Table 2.

Patient clinical and epidemiological characteristics by HPV status, N = 346

		HPV (–)		HPV (+)		HPV (-)	HPV (+)
Characteristic		N	(%) among HPV(-)	N	(%) among HPV(+)	Mean (SD)	Mean (SD)	p-value
Age at Dx (years)		211		135		61.4 (12.3)	57.0 (9.6)	0.0002
Gender	Male	139	66 %	120	89 %			<0.0001
	Female	72	34 %	15	11 %
Cancer Site	Larynx/Glottic	72	34 %	11	8 %			<0.0001
	Oral Cavity	110	52 %	16	12 %
	Oropharynx	20	9 %	105	78 %
	Hypopharynx	9	4 %	3	2 %
Cancer Stage	I/Cis	36	17 %	11	8 %			<0.0001
	II	28	13 %	7	5 %
	III	39	18 %	13	10 %
	IV	108	51 %	104	77 %
Comorbidities (ACE)	None	41	19 %	50	37 %			0.001
	Mild	99	47 %	59	44 %
	Moderate	50	24 %	20	15 %
	Severe	21	10 %	6	4 %
Tobacco Use	Current (within past 12 months)	102	48 %	43	32 %			0.001
	Former (quit > 12 months)	75	36 %	50	37 %
	Never	34	16 %	42	31 %
Pack Years, n = 257	(cigs only)					38.4 (25.6)	29.9 (28.8)	0.02
Pack Years, n = 264	(cigs, cigars, pipe)					41.8 (34.5)	29.6 (29.4)	0.005
Alcohol Use, n = 244	Current (within past 12 months)	63	30 %	27	20 %			0.01
	Former (quit > 12 months)	126	60 %	101	75 %
	Never	22	10 %	7	5 %
Treatment, n = 335	Surg alone	53	26 %	14	11 %			<0.0001
	Rad alone	23	11 %	11	8 %
	Surg + Rad	30	15 %	4	3 %
	Rad + Chemo	45	22 %	93	70 %
	Surg + Rad + Chemo	29	14 %	10	8 %
	No Treatment prior to death	22	11 %	1	1 %
Post Treatment Status	Free of Disease	186	88 %	131	97 %			0.004
	Persistent Disease	25	12 %	4	3 %
KM estimate 2 year RPFT			69 %		84 %			0.001
KM estimate 2 year OST			71 %		91 %			<0.0001

-Percentages will not add to 100 % horizontally. % presented is proportion of clinical or epidemiological subgroup among HPV status category. -p-values calculated by Wilcoxon-rank tests for continuous variables and Kruskal-Wallis tests for categorical variables. Log-rank test used for KM analysis